*Vedlikeholdsbehandling hos voksne med moderat til alvorlig kronisk obstruktiv lungesykdom (kols), som ikke er adekvat behandlet med en kombinasjon av et inhalert kortikosteroid og en langtidsvirkende beta2-agonist eller en kombinasjon av en langtidsvirkende beta2‑agonist og en langtidsvirkende muskarinantagonist.
†Vedlikeholdsbehandling av astma hos voksne som ikke er adekvat kontrollert med en vedlikeholdskombinasjon av en langtidsvirkende beta2‑agonist og middels dose inhalert kortikosteroid, og som opplevde 1 eller flere astmaeksaserbasjoner i foregående år.
‡Vedlikeholdsbehandling av astma hos voksne som ikke er adekvat kontrollert med en vedlikeholdskombinasjon av en langtidsvirkende beta2-agonist og en høy dose inhalert kortikosteroid, og som opplevde minst en astmaeksaserbasjon i foregående år.
Referanser:
1. SPC Trimbow inhalasjonspulver 03.2022, Felleskatalogen.no
2. SPC Trimbow inhalasjonsaerosol, 03.2022 , Felleskatalogen.no
3. Buttini F, Brambilla G, Copelli D, et al. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers. Aerosol Med Pulm Drug Deliv. 2016;29:167–78
4. Corradi M, Chrystyn H, Cosio BG, et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Opin Drug Deliv. 2014;11:1497–506
5. Braido F, Scichilone N, Lavorini F, et al. Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association – GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN). Asthma Res Pract 2016;2:12
6. Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet 2019;394:1737–49
7. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016;388:963–73
8. Singh D, Corradi M, Montagna I, et al. TRINITY: A phase III study to compare the efficacy and safety of an extrafine triple combination of beclometasone dipropionate (BDP), formoterol fumarate (FF), and glycopyrronium bromide (GB) pMDI (CHF5993) with tiotropium (Tio) and a free triple combination of BDP/FF (Foster®) + Tio in COPD patients. Accepted 2016 ERS conference, London: Late breaking topics in airways disease: Oral presentation, Monday September 5. Room C (10:45-12.45)
9. Beeh K-M, Kuna P, Corradi M, et al. Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial. Int J Chron Obstruct Pulmon Dis 2021;16:79–89
10. Lipworth B, Manoharan A, Anderson W. Unlocking the quiet zone: the small airway asthma phenotype. Lancet Respir Med 2014;2:497–506
11. Usmani OS, Scichilone N, Mignot B, et al. Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations. Int J Chron Obstruct Pulmon Dis. 2020;15:2433–40